Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events "CHANCE"

Completed

Phase 3 Results N/A

Summary of Purpose

The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in high-risk patients with TIA or minor stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 11 March 2012.

1 Jul 2008 17 Sep 2009 1 Mar 2012 1 Mar 2012 1 Mar 2012 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts